Morning Movers Gapping up $DoorDash(DASH.US)$stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential. $Roivant Sciences(ROIV.US)$stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study. Gapping down $蔚来(NIO.US)$fell ...
The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.
$Roivant Sciences(ROIV.US)$extremely undervalued, by at least 60%? Roivant stock was already priced at ~ $7 with a market cap of $5 Billion when it licensed RVT-3101 from Pfizer for $45 million back in Dec, 2022. Now Roivant just pocketed $5 billion from selling it to Roche, so its stock price shall at least raise to $14 to justify the huge gain only from the Roche deal by simple math, that's probably also why its average analyst price target is about $16.
MACRO Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets. Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
Analyst David Risinger from Leerink Partners sees the deal as a 'transformative transaction' for Roivant and looks forward to hearing how the company plans to reinvest the cash.
$Roivant Sciences(ROIV.US)$The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to gain rights in the US and Japan to develop and market the drug known as RVT-3101.
1 | Below is a look at the top insider trades with the biggest value in the past week. One of$Immunovant(IMVT.US)$'s directors and more than 10% owner,$Roivant Sciences(ROIV.US)$, recently undertook a vast buy transaction worth $58 million. IMVT stock has gained over 104% since the start of this year. It is worth mentioning that Immunovant is a subsidiary of Roivant Sci...
Roivant Sciences股票讨论区
专栏Today's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More
Gapping up
$DoorDash(DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences(ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$蔚来(NIO.US)$ fell ...
Ph2 readouts in Q1 2024...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
专栏Wall Street Today | Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets.
Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
Loading this
News
专栏Weekly Insider Money Tracking: IMVT director undertook a $58 million buy, and AAPL executives sold over $64 million in stocks.
One of $Immunovant(IMVT.US)$'s directors and more than 10% owner, $Roivant Sciences(ROIV.US)$, recently undertook a vast buy transaction worth $58 million. IMVT stock has gained over 104% since the start of this year. It is worth mentioning that Immunovant is a subsidiary of Roivant Sci...
暂无评论